Details of the Drug Reposition

General Information of This Drug (ID: DMZXF05)

Drug Name
GTx-024   DMZXF05
Synonyms
(R)-Ostarine; 1132656-73-5; (2R)-3-(4-Cyanophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide; C19H14F3N3O3; 841205-47-8 pound not1202044-20-9; SCHEMBL2197534; CHEBI:94527; DTXSID70649384; BCPP000135; AOB87717; ZINC35793633; BCP9001038; NCGC00408913-01; AS-17044; FT-0673314; Y0247; 370C134; I06-2154; BRD-K16621777-001-01-9; (R)-N-(4-Cyano-3-(trifluoromethyl)phenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Muscle atrophy DISL46JF FB32.Y Phase 3 [1]
------------------------------------------------------------------------------------
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Breast cancer DIS7DPX1 2C60-2C65 Phase 2 [2]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT01355497) Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)